Clinical trials: Rituximab
Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma
Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
This clinical trial is a multicentric prospective study to assess the clinical and prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.
- Trial name
- SARCOPENIE (NCT01715961)
- Testing
- anthropometric measurement
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Centre Henri Becquerel
Autoimmune Diseases
Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus
Several clinical studies have shown that rituximab is safe and effective for the induction of remission in moderate to severe systemic lupus erythematosus, and has been recommended by several guidelines for the induction of…
- Trial name
- NCT04127747
- Testing
- Standard dose of rituximab, Individualized dose of rituximab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Leukemia
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00562328
- Testing
- Alemtuzumab, Rituximab, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Follicular Lymphomas, Immunocytomas
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no…
- Conditions
- Follicular Lymphomas, Immunocytomas, Marginal Zone Lymphomas, Mantle-Cell Lymphomas
- Trial name
- MAINTAIN (NCT00877214)
- Testing
- Rituximab, Rituximab / observation
- Where
- Germany
- Volunteers
- 1,272 people
- Sponsor
- Jurgen Barth
Nephrotic Syndrome
Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome
Double-blind, two-parallel-arm, placebo-controlled randomized clinical trial testing the superiority of Ofatumumab versus placebo in the treatment of children with DR-INS.
- Trial name
- NCT02394106
- Testing
- Ofatumumab
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Istituto Giannina Gaslini
PCNSL
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
It is a multicenter, open-Label, randomised phase 2 study to compare the efficacy and safety study of R2-MTX chemotherapy（Lenalidomide, Rituximab and Methotrexate）with R-MTX chemotherapy（Rituximab and Methotrexate ）as first-line…
- Trial name
- NCT04481815
- Testing
- Rituximab, Lenalidomide, Methotrexate
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks.
- Trial name
- NCT07270835
- Testing
- Rituximab, Zanubrutinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Membranous Nephropathy
Rituximab in Membranous Nephropathy
Membranous glomerulopathy (MN) is a common immune-mediated glomerular disease and the leading cause of nephrotic syndrome in Caucasian adults.
- Trial name
- NCT00425217
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
The hypothesis is that a subset of patients with chronic fatigue syndrome/ myalgic encephalomyelitis (CFS/ME), including also patients with no clinical response after B-cell depletion therapy using the anti-CD20 antibody…
- Trial name
- NCT01730495
- Testing
- Etanercept
- Where
- Norway
- Volunteers
- 4 people
- Sponsor
- Haukeland University Hospital
FSGS, Proteinuria
Rituximab to Prevent Recurrence of Proteinuria
The investigators propose to study novel targets of rituximab in podocytes, with a particular focus on recurrent focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT01164098
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- George W. Burke
Lymphoma
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00881387
- Testing
- rituximab, gemcitabine hydrochloride, vinorelbine ditartrate
- Where
- United States
- Sponsor
- University of Miami
Myasthenia Gravis
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
- Trial name
- NCT02110706
- Testing
- Rituximab
- Where
- 26 sites in United States
- Volunteers
- 52 people
- Sponsor
- Yale University
Primary Focal Segmental Glomerulosclerosis
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional…
- Trial name
- NCT01573533
- Testing
- Rituximab
- Where
- 4 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Mantle Cell Lymphoma
Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma
Patients with mantle cell lymphoma have a grave prognosis. They usually have an initial response to therapy, however progress early in the course of the disease and have very poor survival.
- Trial name
- NCT00586755
- Testing
- Intensive Induction-BMT
- Volunteers
- 48 people
- Sponsor
- Duke University
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the…
- Trial name
- NCT02315326
- Testing
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX)
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Transplant Recipients
Research Study of ATG and Rituximab in Renal Transplantation
The purpose of this study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long term immunosuppressive medication.
- Trial name
- RESTARRT (NCT01318915)
- Testing
- ATG, Rituximab, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Solid Tumor
National Project on Vaccines, COVID-19 and Frail Patients
This is a multicentre observational study with the aim of evaluating the antibody and cellular response after vaccination for SARS-CoV-2 with Pfizer-BioNTech or Moderna vaccines in frail subjects with impaired immuno-competence…
- Conditions
- COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder
- Trial name
- VAX4FRAIL (NCT04848493)
- Testing
- COVID-19 vaccines
- Where
- 12 sites in Italy
- Volunteers
- 747 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Nonneoplastic Condition
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura
RATIONALE: Rituximab and prednisone may increase the number of platelets in patients with immune thrombocytopenic purpura. PURPOSE: This phase II trial is studying the side effects and how well giving rituximab together with…
- Trial name
- NCT00486421
- Testing
- Rituximab, Prednisone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
- Trial name
- NCT01682616
- Testing
- ABT-199, Rituximab
- Where
- 6 sites in United States, Australia
- Volunteers
- 49 people
- Sponsor
- AbbVie
Immune Thrombocytopenia, Treatment
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with Rituximab in pediatric ITP patients.This study will be conducted in pediatric ITP patients who had not…
- Trial name
- NCT07362238
- Testing
- Rituximab, Daratumumab
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China